Mind + Muscle

technical minds + legal muscle

Bracket

dig deep

Sterne Kessler Director Authors U.S. Biotechnology Patent Law

  • 10.06.16

WASHINGTON, DC (October 6, 2016) - Sterne, Kessler, Goldstein & Fox P.L.L.C. is proud to announce the publication, by Thomson Reuters, of U.S. Biotechnology Patent Law. This is a highly readable and well-organized desktop companion for practicing attorneys (i.e., prosecutors, litigators or inside counsel), patent agents, and students, who are seeking effortless entry into case law dealing with patents in modern biotechnology. The text, authored by firm director Jorge A. Goldstein, Ph.D., focuses on biotechnology cases decided by the Court of Appeals for the Federal Circuit, its predecessor, the Court of Customs and Patent Appeals, the U.S. Supreme Court, and the U.S. Patent and Trademark Office Appellate Boards.

The casebook highlights prominent biotech case-law and, for each case discussed, includes a summary of the holding, separate patent claims, technology drawings or other facts needed for a clearer understanding, and verbatim citations and quotes from the tribunal. Throughout the publication, Dr. Goldstein includes comments discussing trends in the case law, critiques of outlier cases, and attempts to provide unifying themes to the historical and thematic development of the law. Also included are summary diagrams that provide immediate understanding of a body of case law, such as, for example, the development of a drug from early research to a time after approval by the FDA.

U.S. Biotechnology Patent Law distills my 40 years' experience pioneering the highly technical and specialized field of biotechnology patent law. It is my sincere hope that this text (and its planned updates) will help inspire and educate the lawyers and patent agents who will secure and litigate patents for the next generation of biotech breakthroughs,” said Dr. Goldstein.

U.S. Biotechnology Patent Law is being published both in paper and online versions and is available for purchase from Thomson Reuters.

About the Author:
A pioneer in biotechnology patent law and founding partner of Sterne Kessler, Jorge A. Goldstein, Ph.D., has almost forty years’ experience in preparing, prosecuting, licensing, enforcing and litigating biotech patents before the U.S. and foreign patent offices and tribunals. Dr. Goldstein is also the founder of the firm’s unique pro bono practice dedicated to integrating intellectual property law concepts with economic, social, and cultural rights to empower disenfranchised and impoverished communities' economic and social development. Dr. Goldstein received his J.D. from The George Washington University with high honors, his Ph.D. in Chemistry from Harvard, and his B.S. in Chemistry from Rensselaer Polytechnic Institute.

About Sterne Kessler:
Founded in 1978 and based in Washington, DC, Sterne Kessler is dedicated exclusively to the protection, transfer, and enforcement of intellectual property rights. Our team of attorneys, registered patent agents, students and technical specialists include some of the country's most respected practitioners of intellectual property law. Most of our professionals hold an advanced level degree, including more than 55 masters degrees and almost 55 with a doctorate in science or engineering -- credentials wide and deep enough to fill the faculty of a science-oriented university.

Media Contact:
Kathryn Holmes Johnson
+1 202.772.8925
kholmesjohnson@skgf.com 

###

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar
X

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.